E815
TEAS SECTION 8 & 15 RECEIVED
07/09/2026
Back to search
Official data from USPTO
IOVANCE BIOTHERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
47
Latest update
07/09/2026
Classification
Registered
Trademark type
Combined
Nice classes
1, 5, 44
Filing date
06/23/2017
Registration date
01/21/2020
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/21/2020
Last transaction
07/09/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
04/17/2019
First use in commerce
04/17/2019
Drawing code
3
Owner type
03
Owner location
SAN CARLOS, CA, US
Examiner
ORTIGA PALMER, RAMONA
Law office
M80
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the word "IOVANCE" above the word "BIOTHERAPEUTICS", with a stylized "O" in "IOVANCE" consisting of a crescent shape opening to the bottom left corner and five smaller crescent shapes opening to the upper right corner.
Holders and representatives
Holders
IOVANCE BIOTHERAPEUTICS, INC.
Lion Biotechnologies, Inc.
Representatives
Carla B. Oakley MORGAN, LEWIS & BOCKIUS LLP
Technical classification
Nice Classes
Class 1Class 5Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Cells for cancer treatment research; chemical preparations for use in clinical research; biological tissueshuman cells for use in scientific and medical research
Class 5
Pharmaceuticals for the treatment of oncological disease and disorders; pharmaceutical preparations for use in immunotherapy for the treatment of oncological disease and disorders
Class 44
Medical servicesmodifying cells for the treatment of cancer and other diseases and medical conditions; immunotherapy treatments; medical diagnostic and treatment services; providing information in the field of oncology and immunotherapy treatments; providing medical informationconsultancy and advisory services
Publications
History of USPTO decisions and trademark events.
47 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/10/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/10/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/10/2026
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
01/21/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/23/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/23/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/23/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/23/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/23/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
01/21/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
12/18/2019
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
12/17/2019
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
11/28/2019
SUPC
STATEMENT OF USE PROCESSING COMPLETE
11/27/2019
DPCC
DIVISIONAL PROCESSING COMPLETE
11/27/2019
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
11/27/2019
IUAF
USE AMENDMENT FILED
11/08/2019
DRRR
DIVISIONAL REQUEST RECEIVED
11/08/2019
EISU
TEAS STATEMENT OF USE RECEIVED
11/08/2019
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
11/08/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/10/2019
EX2G
SOU EXTENSION 2 GRANTED
05/08/2019
EXT2
SOU EXTENSION 2 FILED
05/08/2019
EEXT
SOU TEAS EXTENSION RECEIVED
05/08/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/09/2018
EX1G
SOU EXTENSION 1 GRANTED
11/07/2018
EXT1
SOU EXTENSION 1 FILED
11/07/2018
EEXT
SOU TEAS EXTENSION RECEIVED
11/07/2018
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
05/08/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/13/2018
PUBO
PUBLISHED FOR OPPOSITION
03/13/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/21/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/01/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
01/29/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/29/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
01/29/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/29/2018
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
09/27/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/12/2017
GNRT
NON-FINAL ACTION E-MAILED
09/12/2017
CNRT
NON-FINAL ACTION WRITTEN
09/12/2017
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
09/06/2017
DOCK
ASSIGNED TO EXAMINER
09/02/2017
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
07/01/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/30/2017
NWAP
NEW APPLICATION ENTERED
06/27/2017
Continuous trademark protection
Get notified about every new filing that threatens IOVANCE BIOTHERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.